Just when the world had begun to settle into post-pandemic normalcy, a new COVID-19 variant has entered the spotlight—Stratus, a name now making headlines across the UK. If you haven’t heard of it yet, you will. Stratus, specifically its XFG and XFG.3 sub-variants, is spreading quickly and has prompted health experts to take notice.

There’s no reason to panic. The variant isn’t known to cause more severe illness or to evade current vaccines. But it is worth understanding, especially as COVID continues to evolve and resurface in new forms. The story of Stratus offers insight not just into the virus itself, but how we’ve learned to live alongside it—through better surveillance, faster response, and smarter precautions.

What Is the Stratus Variant?

Stratus is not a completely new virus—it’s a descendant of the Omicron lineage, already known for its ability to spread easily while generally causing milder illness than earlier strains like Delta.

More specifically, Stratus is what experts call a “recombinant” strain, formed when someone is infected with two variants at once and those variants mix their genetic material. This gives Stratus its nickname: the “Frankenstein” variant. There are two types of Stratus in circulation:

XFG

XFG.3, a spin-off which currently accounts for about 30% of COVID-19 cases in England, up from just 10% in May, according to the UK Health Security Agency (UKHSA).

Because of its rapid spread, the World Health Organization (WHO) has classified XFG as a "variant under monitoring", urging global surveillance.

What Makes Stratus Variant Different From Other COVID Strains?

Though most symptoms of COVID haven’t changed much with each variant, Stratus may come with a new, unusual symptom: a hoarse voice.

According to some UK-based clinicians, patients infected with XFG and XFG.3 have reported hoarseness more frequently. This could be a result of the strain’s impact on the upper respiratory tract, particularly the vocal cords but here’s the thing: this is not yet a definitive diagnostic marker. Hoarseness alone doesn’t confirm infection, and not everyone with Stratus reports it. Like other variants, symptoms remain largely dependent on the person’s immune response, vaccination status, and pre-existing conditions.

What Are the Unique COVID Symptoms of Stratus?

While Stratus may bring hoarseness into the conversation, the core symptoms of COVID remain largely the same. According to the NHS and UKHSA, people infected with Stratus may experience:

• High temperature or chills
• Persistent cough
• Shortness of breath
• Loss or change in taste or smell
• Fatigue
• Headaches
• Muscle aches
• Sore throat
• Nasal congestion or runny nose
• Loss of appetite
• Diarrhea or nausea

These symptoms also overlap with seasonal flu and allergies, making it difficult to identify the variant without testing. What makes Stratus stand out so far is its hoarseness, which might be more pronounced than in previous infections.

Is Stratus COVID Variant More Dangerous?

The WHO and UKHSA have both made it clear: there’s no current evidence that Stratus leads to more severe illness, higher hospitalization rates, or death compared to other Omicron subvariants.

Dr. Alex Allen, a consultant epidemiologist at UKHSA, explained that there is no indication vaccines are less effective against Stratus. In fact, immunity—whether from vaccines, previous infection, or both—continues to offer protection, especially against serious outcomes.

It’s also worth noting that hospital admissions and case rates in the UK have been trending downward, despite the rise of Stratus. As of late June, COVID hospitalizations in England dropped from 1.46 per 100,000 to 0.99 per 100,000.

This suggests that while XFG and XFG.3 are spreading fast, they may not be driving a significant wave of severe disease.

Why Is Stratus Being Monitored?

Even though it isn’t more dangerous right now, Stratus is spreading quickly—and that alone is enough reason to monitor it closely.

The WHO notes that XFG exhibits “marginal additional immune evasion” compared to previously circulating strains. In plain terms: it might slip past some parts of the immune system, but not enough to trigger alarm bells. Still, it has been seen in multiple countries, especially in South-East Asia, where some upticks in hospitalizations have occurred.

That doesn’t mean we’re on the brink of another global surge. It does mean that global health systems remain vigilant, especially as colder months approach in the Northern Hemisphere.

How to Protect Yourself from New COVID Variants?

No matter the strain—whether it’s Delta, Omicron, or now Stratus—the same precautions still apply:

• Stay up to date on vaccinations, including boosters recommended by your local health authority.
• Test when symptomatic, especially if you’re at high risk or around vulnerable individuals.
• Practice good hygiene: wash your hands, cover your cough, and sanitize high-touch surfaces.
• Wear a mask in crowded indoor spaces if transmission is high in your area.
• Take hoarseness seriously if it appears alongside other symptoms—especially if you’ve had recent exposure.

You might be asking: If Stratus isn’t more deadly, why should I care? Here’s why. Pandemics don’t end with a bang—they evolve quietly. Variants like Stratus remind us that SARS-CoV-2 is still adapting, and we need to stay informed even when things seem calm. By recognizing symptoms early, getting tested, and staying up to date on guidance, we help protect not only ourselves but the most vulnerable among us.

So no, Stratus isn’t a reason to panic but it is a reason to pay attention because COVID hasn’t disappeared—it’s just changed its voice.

A landmark study titled “COVID-19 Vaccine Linked to Longer Survival in Cancer Patients” has revealed that people with advanced lung or skin cancer who received an mRNA COVID-19 vaccine within 100 days of starting immunotherapy lived significantly longer than those who did not. Conducted by researchers from the University of Florida (UF) and the University of Texas MD Anderson Cancer Center, the findings were presented at the 2025 European Society for Medical Oncology Congress in Berlin and mark a major step in exploring how mRNA technology could strengthen cancer treatment.

A Milestone in mRNA Research

This study represents the culmination of more than a decade of UF research on mRNA-based cancer therapies. Lead investigator Dr Elias Sayour, a pediatric oncologist at UF Health, called the findings “extraordinary,” noting that the vaccine’s immune-boosting effect could help design a universal, off-the-shelf cancer vaccine capable of enhancing immunotherapy responses.

mRNA, or messenger RNA, is a molecule that carries genetic instructions to make proteins. It forms the basis of COVID vaccines developed during the pandemic, and scientists now believe this same mechanism could be harnessed to amplify the body’s cancer-fighting abilities.

How the Study Was Conducted

Researchers analyzed medical records of over 1,000 patients with stage III and IV non-small-cell lung cancer or metastatic melanoma treated at MD Anderson between 2019 and 2023. Of these, 180 lung-cancer patients and 43 melanoma patients received a COVID-19 mRNA vaccine within 100 days of starting immunotherapy. Their outcomes were compared with 704 and 167 unvaccinated patients, respectively.

The results were striking. Vaccinated lung-cancer patients showed a median survival of 37.3 months, nearly double the 20.6 months observed in unvaccinated counterparts. Among melanoma patients, survival rose from 26.7 months to about 30–40 months, with several patients still alive at data cut-off — suggesting an even greater long-term benefit.

Importantly, the effect was specific to mRNA COVID vaccines; flu and pneumonia shots did not produce similar outcomes.

The Science Behind the Boost

Earlier this year, Dr Sayour’s lab discovered that to trigger a strong immune attack, targeting a single tumor protein wasn’t necessary. Instead, stimulating the immune system as if fighting a viral infection worked better. When this nonspecific mRNA vaccine was combined with immune checkpoint inhibitors — drugs that “release the brakes” on immune cells — mice showed powerful antitumor responses.

Building on this, the team theorized that the COVID mRNA vaccine might act like an immune flare, mobilizing immune cells from tumor zones to lymph nodes where cancer defense is stronger. This mechanism, Sayour explained, could make previously unresponsive cancers respond to treatment.

Implications and Next Steps

Although this is an observational study and cannot yet prove causality, experts are optimistic. UF’s Dr Duane Mitchell emphasized that while more trials are needed, such a large survival benefit “is the type of treatment effect we rarely see.”

A large-scale clinical trial through the UF-led OneFlorida+ Research Network is now planned to verify these findings across hospitals in several U.S. states.

If confirmed, the discovery could reshape how cancer is treated — turning vaccines from preventive tools into active partners in therapy. For patients battling advanced cancers, this could mean something profoundly valuable: more time and renewed hope.

Every year on October 20, World Osteoporosis Day is marked, to put the spotlight on osteoporosis. The day marks a year-long campaign, which is dedicated to raising global awareness of bone health, and the prevention, diagnosis and treatment of osteoporosis and related musculoskeletal diseases.

Osteoporosis is a serious condition where bones lose its density and strength, and it thus makes them fragile and more likely to break. It is often called the 'silent disease', and most people don't even realize that they have it until a fracture happens.

The most common fracture in this condition is in hip, spine, wrist, or shoulder. These fractures can result in long hospital stays, and lead to loss of independence, and reduced quality of life.

World Osteoporosis Day 2025 Theme

This year's theme is 'It's Unacceptable'.

This puts the spotlight on the persistent and preventable crisis in osteoporosis care.

This condition affects over 500 million people worldwide, and most remain severely underdiagnosed and undertreated. Up to 80% of patients with osteoporotic fractures do not receive any follow-up diagnosis or treatment.

This theme furthermore makes an effort for everyone to make noise for the silent disease.

The disease is more common among women, as 1 in 3 women, as compared to 1 in 5 men aged 50+ are prone to osteoporotic fracture in their remaining lifetime. These fractures could lead to chronic pain and disability, loss of independence, increased risk of further fractures, and even premature deaths.

Thus the theme 'It's Unacceptable', highlights that it is simply unacceptable that patients continue to receive inadequate care, and people are still not aware of the condition.

Origin Of World Osteoporosis Day

The World Osteoporosis Day was first launched in 1996 by the United Kingdom's National Osteoporosis Society, with support from the European Commission. The International Osteoporosis Foundation (IOF), then took over the global coordination in 1997, turning it into a worldwide awareness campaign that takes place annually on October 20. The World Health Organization (WHO) also co-sponsored the event in 1998 and 1999, helping to raise its international profile.

Significance of World Osteoporosis Day 2025

Why is it important to observe a day on this, internationally? The reason is, this condition is very common, is among the most frequent health events, yet not much talked about. The IOF notes that in women osteoporotic fractures are more common than breast cancer. Women who are over the age of 45 account for more days in hospital than many other diseases, if they are osteoporotic. This comparison is done with other chronic diseases, including diabetes, myocardial infarction, and even breast cancer, notes IOF.

For men, in many countries, osteoporotic fractures account for more hospital bed days than those due to prostrate cancer.

IOF notes that osteoporosis is not prioritized in healthcare policy, and that it continues to be underdiagnosed and undertreated, globally. Only 1 in 3 vertebral fractures come to clinical attention, and most spinal fractures are often diagnosed as simple 'back pain'. This is why there remains a high treatment gap. In Europe, 72% of women who are at a high risk of osteoporotic fractures do not receive treatment.

This is why awareness about this condition becomes more so important, especially when framing public policies, education campaigns, and preventative care, especially making people understand the importance of calcium and vitamin D.

Glenmark, a leading Indian drugmaker, has recalled its products in the US over manufacturing issue, confirmed the US Food and Drug Administration (USFDA).

What Did The USFDA Say?

The USFDA released an Enforcement Report, which noted that the US-based unit of Glenmark Pharmaceuticals in recalling 26,928 packs of oral contraceptive medicines in the US. The company's unit based in Mahwah, New Jersey, has now recalled the affected lot of the following birth control pills:

• Viorele
• Desogestrel
• Ehinyl Estradiol

The report also noted that Ethinyl Estradiol tablets were recalled due to "failed impurities and degradation specifications". The affected drugs were produced in the company's Mumbai headquarters' Goa manufacturing facility. This is because India has the highest number of USFDA-compliant pharmaceutical plants outside of the US.

The drug firm also issued a notice for Class II nationwide recall on September 3, 2025.

What Does Class II Recall Mean?

The USFDA notes that recalls are actions taken by the firm to remove and product from the market and could be conducted by company's own initiative, or by the FDA request or order.

Class II recall means a situation in which the use of or the exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequence is remote.

What Are The Different Categories Of Recalls?

As per the USFDA, there are 5 different categories of recalls, namely:

• Class I Recall
• Class II Recall
• Class II Recall
• Market Withdrawal
• Medical Device Safety Alert

• Class I recall: a situation in which there is a reasonable probability that the use of or exposure to a violative product will cause serious adverse health consequences or death.

• Class II recall: a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.

• Class III recall: a situation in which use of or exposure to a violative product is not likely to cause adverse health consequences.

• Market withdrawal: occurs when a product has a minor violation that would not be subject to FDA legal action. The firm removes the product from the market or corrects the violation. For example, a product removed from the market due to tampering, without evidence of manufacturing or distribution problems, would be a market withdrawal.

• Medical device safety alert: issued in situations where a medical device may present an unreasonable risk of substantial harm. In some case, these situations also are considered recalls.

Are There Any Other Drugs Being Recalled?

Dr Reddy's Laboratories, another major Indian drugmaker, has also recalled its muscle relaxant in the US. The company's Princeton, New Jersey-based subsidiary has recalled 571 vials of Succinylcholine Chloride Injection. The recall was initiated due to "out-of-specification results during the 6-month stability testing," according to USFDA.